Medicineen
FDA Grants Approval for New Gene Therapy to Treat Recurrent Respiratory Papillomatosis
The new biological treatment aims to reduce the frequency of surgical excisions for adults suffering from the chronic condition.


PENN Explainer
Hear this story explained in 90 seconds.
The United States Food and Drug Administration has officially approved a new biological treatment for adults diagnosed with recurrent respiratory papillomatosis. This condition causes non-cancerous growths to develop in the respiratory tract, often requiring frequent and invasive surgical procedures to remove them. The newly authorized therapy, known as doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd, is designed to lower the frequency of these necessary surgical excisions. The approval was confirmed in an official letter issued by the agency on October 30, 2026.
This development marks a significant step forward for patients who have historically relied on repeated surgeries to manage their symptoms. The clinical review process for this product was linked to the National Clinical Trial number NCT04398433. Under the terms of the approval, the manufacturer is required to adhere to specific post-marketing study requirements to ensure ongoing safety and efficacy monitoring. These requirements include submitting detailed reports every 180 days for all open studies associated with the treatment.
The drug substance will be manufactured at the Alliance Medical Products facility located in Irvine, California. The final product will also undergo labeling and packaging processes at the same site. Agency officials noted that the clinical study design and the resulting trial data did not raise any controversial issues that would have required an advisory committee discussion. This streamlined review process reflects the urgent medical need for effective, non-surgical options for this patient population.
The approval falls under accelerated approval statutory provisions, which allow for the marketing of biological products that address serious conditions. Moving forward, the manufacturer must continue to provide data to the agency to confirm the clinical benefits of the therapy. This ongoing oversight is a standard procedure for treatments granted under these specific regulatory pathways. Patients and healthcare providers can expect more information regarding the availability and administration of the therapy in the coming months.
You've reached your free article limit
You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.
Already a subscriber? Sign in.
Ask the Author
Subscribers can ask the journalist a question about this story. Subscribe to ask.
Neutrality note
Auto-harvested from global news wires and presented neutrally by PENN.
to vote
Comments
No comments yet — be the first to share your thoughts.



